Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

Journal:

Nature Communications

Published:

2025-05-09

DOI:

10.1038/s41467-025-59588-3

Affiliations:

7

Authors:

18

Go to article

Institutions	Authors	Share
Genentech, Inc., United States of America (USA)	11.000000 11.000000	0.61
Foundation Medicine, Inc., United States of America (USA)	3.000000	0.17
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.06
Asan Medical Center (AMC), South Korea	1.000000	0.06
University of Campania Luigi Vanvitelli, Italy	1.000000	0.06
Sarah Cannon Research Institute (SCRI), United States of America (USA)	0.500000	0.03
Tennessee Oncology, United States of America (USA)	0.500000	0.03

Interested in Oncology and Carcinogenesis?